William Howitt, MD
Family Medicine · Springfield, MONPI 1306834288
Payments from drug & device makers
Across 398 payments — averaging $49,931 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$14.7M
- Pfizer$1.3M
- Vanda Pharmaceuticals Inc.$1.2M
- Merck$822K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$815K
- Antares Pharma, Inc.$734K
- plus $274K from 30 others
Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
What the payments were for
- Food & beverage$2,948100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 7 | $14,663,362 |
| Pfizer | 134 | $1,346,767 |
| Vanda Pharmaceuticals Inc. | 23 | $1,216,603 |
| Merck | 19 | $822,358 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $814,710 |
| Antares Pharma, Inc. | 16 | $734,220 |
| DPT Laboratories, Ltd. | 3 | $240,423 |
| E.r. Squibb & Sons, L.L.C. | 1 | $31,349 |
| Supernus Pharmaceuticals, Inc. | 42 | $488 |
| AbbVie(2 entities) | 27 | $429 |
| AstraZeneca | 24 | $424 |
| Novo Nordisk | 14 | $189 |
| Lilly USA, LLC | 11 | $176 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $167 |
| GSK | 6 | $88 |
| Amgen | 5 | $85 |
| Otsuka America Pharmaceutical, Inc. | 5 | $66 |
| Astellas Pharma US Inc | 4 | $61 |
| Johnson & Johnson | 4 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $55 |
| Dexcom, Inc. | 2 | $36 |
| Sanofi | 1 | $27 |
| Collegium Pharmaceutical, Inc. | 2 | $26 |
| Abbott | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $18 |
| Gilead | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Organon | 1 | $13 |
| Novartis | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
| Aytu Biopharma, Inc. | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
How this compares
$19,872,355 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 19 | $20,125 |
| XareltoRivaroxaban | 12 | $7,359 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 112 | $4,386 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 71 | $2,510 |
| Pregabalin | 60 | $1,032 |
| Oxycodone Hcl | 34 | $658 |
| Levocetirizine Dihydrochloride | 20 | $551 |
| Sertraline Hcl | 25 | $502 |
| Bupropion Hcl SrBupropion Hcl | 12 | $486 |
| Testosterone Cypionate | 20 | $438 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 11 | $411 |
| Tramadol Hcl | 41 | $396 |
| Minocycline Hcl | 11 | $343 |
| Potassium Chloride | 14 | $334 |
| Diazepam | 38 | $258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $1,346,767 | $20,12519 claims |
| Johnson & JohnsonXarelto | $58 | $7,35912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Springfield
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Stephen AdamsSpringfield$636K
- Cory BethmannSpringfield$621K
- Roger CadySpringfield$175K
- Don BrockmanSpringfield$31K
- James van RiessenSpringfield$25K
- Timothy JenningsMaryland Heights$30.2M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.